

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/023255 A1

(43) International Publication Date
23 February 2023 (23.02.2023)

(51) International Patent Classification:

C07D 471/04 (2006.01) *A61P 29/02* (2006.01)
C07D 519/00 (2006.01) *A61P 35/00* (2006.01)
A61P 3/00 (2006.01) *A61K 31/498* (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/040765

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

18 August 2022 (18.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/234,606 18 August 2021 (18.08.2021) US

(71) Applicants: **NURIX THERAPEUTICS, INC.** [US/US];

1700 Owens Street, Suite 205, San Francisco, California
94158 (US). **GILEAD SCIENCES, INC.** [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **PALMER, Wylie**; c/o Nurix Therapeutics, Inc.,

1700 Owens Street, Suite 205, San Francisco, California
94158 (US). **WU, Jeffrey**; c/o Nurix Therapeutics, Inc.,
1700 Owens Street, Suite 205, San Francisco, California
94158 (US). **LEE, John**; c/o Nurix Therapeutics, Inc., 1700
Owens Street, Suite 205, San Francisco, California 94158
(US). **OZBOYA, Kerem**; c/o Nurix Therapeutics, Inc.,
1700 Owens Street, Suite 205, San Francisco, California
94158 (US). **KANE, Tim**; c/o Nurix Therapeutics, Inc.,
1700 Owens Street, Suite 205, San Francisco, California
94158 (US).

(74) Agent: **HAN, Hai** et al.; Seed Intellectual Property Law

Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Wash-
ington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF

(57) Abstract: The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.



WO 2023/023255 A1